CoolSculpting Non-Surgical Fat Reduction

CoolSculpting cryolipolysis delivers controlled cooling to selectively freeze and permanently eliminate small, localised areas of fat without surgery, needles, or downtime. Not a weight-loss treatment — designed for targeted reduction of stubborn fat pockets that resist diet and exercise. Sessions run approximately thirty to sixty minutes per area. Results develop progressively over two to three months as the body clears treated fat cells.

Cosmos Clinic in Double Bay, Sydney, offers CoolSculpting cryolipolysis as a non-surgical complement to its surgical liposuction services, providing a needle-free and incision-free option for patients with small, localised fat deposits who prefer to avoid surgery. CoolSculpting uses the Zeltiq platform to apply precisely controlled cooling through a vacuum applicator placed against the skin surface. The temperature is lowered to the point where subcutaneous fat cells undergo cryoapoptosis — a natural cell death triggered by cold exposure — while the overlying skin, nerves, and blood vessels remain unaffected, as these tissues tolerate the cooling temperature without damage. Over the two to three months following treatment, the body's lymphatic system and macrophages clear the disrupted fat cells, producing a progressive and gradual reduction in the treated fat layer. CoolSculpting at Cosmos Clinic is positioned as a body contouring tool for stubborn, localised fat areas that resist diet and exercise — not as a weight-loss solution or a substitute for Vaser liposuction in patients requiring larger volume reduction. Common treatment areas include the lower abdomen, flanks (love handles), inner and outer thighs, bra-line back fat, upper arms, and the submental area under the chin. Each applicator session runs approximately thirty to sixty minutes; multiple applicators or sessions may be scheduled for larger or multiple areas. There is no recovery period, and most patients return to normal activity immediately. The clinic notes that paradoxical adipose hyperplasia (PAH) — a rare adverse event in which fat in the treated area paradoxically enlarges — can occur and is discussed as part of the informed consent process.